Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Transplantation Proceedings

• Publication date

  2007-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.TRANSPROCEED.2007.08.078PMID 18021973
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma.

  2007cited by this paper
• Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.

  2007cited by this paper
• Intra-operative continuous veno-venous hemodiafiltration (CVVHDF) during combined liver-kidney transplantation in two patients with primary hyperoxaluria

  2007cited by this paper
• Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

  2006cited by this paper
• Sirolimus-induced remission of posttransplantation lymphoproliferative disorder.

  2006cited by this paper
• Conversion to sirolimus in renal transplant patients with tumors.

  2006cited by this paper
• Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer

  2005cited by this paper
• Regression of Kaposi's sarcoma in renal graft recipients after conversion to sirolimus treatment.

  2005cited by this paper
• Low Incidence of Malignancy among Sirolimus/Cyclosporine-Treated Renal Transplant Recipients

  2005cited by this paper
• Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders.

  2005cited by this paper
• Sirolimus for Kaposi's sarcoma in renal-transplant recipients.

  2005cited by this paper
• Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimus.

  2005cited by this paper
• RAPAMYCIN PROTECTS ALLOGRAFTS FROM REJECTION WHILE SIMULTANEOUSLY ATTACKING TUMORS IN IMMUNOSUPPRESSED MICE

  2004cited by this paper
• Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma.

  2004cited by this paper
• Sirolimus for pediatric liver transplant recipients with post‐transplant lymphoproliferative disease and hepatoblastoma *

  2004cited by this paper
• Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

  2004cited by this paper
• Rapamycin is an effective inhibitor of human renal cancer metastasis.

  2003cited by this paper
• Mammalian target of rapamycin: a new molecular target for breast cancer.

  2003cited by this paper

• Treatment of Merkel cell carcinoma in organ transplant recipients—A systematic review

  2025cites this paper
• The IPTA Nashville consensus conference on post‐transplant lymphoproliferative disorders after solid organ transplantation in children: IV‐consensus guidelines for the management of post‐transplant lymphoproliferative disorders in children and adolescents

  2024cites this paper
• Risk Factors Associated with PTLD Related Mortality in Adult Multivisceral Transplant Recipients - A Single Centre Cohort Study.

  2024cites this paper
• Personalized immunosuppression after kidney transplantation

  2022cites this paper
• Malignancies in renal transplant recipients: A retrospective single-center descriptive study

  2021cites this paper
• Renal Cell Carcinoma and Kidney Transplantation: A Narrative Review

  2021cites this paper
• Epstein-Barr virus-associated post-transplant lymphoproliferative disorders: beyond chemotherapy treatment

  2021cites this paper
• Cancer in Dialysis and Transplant Patients

  2019cites this paper
• Aggressive primary cutaneous CD30+ lymphoproliferative disorder in an organ transplant recipient in sustained complete remission with brentuximab vedotin

  2018cites this paper
• Эффективность поздней конверсии с микофенолатов на эверолимус у реципиентов почечного трансплантата с сопутствующими онкологическими заболеваниями

  2018cites this paper
• Genetic Diversity and Disease Susceptibility

  2018cites this paper
• Merkel cell carcinoma of the eyelid and orbit.

  2018cites this paper
• Gene Polymorphisms of Immunosuppressants in Solid Organ Transplantation

  2018cites this paper
• Kidneys With Small Renal Cell Carcinoma Used in Transplantation After Ex Vivo Partial Nephrectomy.

  2018cites this paper
• An update on cancer after kidney transplantation.

  2018cites this paper
• Cancer in kidney transplant recipients

  2018cites this paper
• Conversion to mammalian target of rapamycin inhibitors in kidney transplant recipients with de novo cancers

  2017cites this paper
• Title Conversion to mammalian target of rapamycin inhibitors inkidney transplant recipients with de novo cancers

  2017cites this paper
• An Update on Calcineurin Inhibitor-Free Regimens: The Need Persists, but the Landscape has Changed.

  2016cites this paper
• Renal Squamous Cell Carcinoma of a Native Kidney After Renal Transplant: A Case Report.

  2016cites this paper
• Herpesvirus Respiratory Infections in Immunocompromised Patients: Epidemiology, Management, and Outcomes

  2016cites this paper
• Renal Tumor in Allogeneic Kidney Transplant Recipient.

  2016cites this paper
• Administration of anti-neoplastic agents to treat malignancies in solid organ transplant recipients

  2015cites this paper
• Administration of antineoplastic agents to treat malignancies in solid organ transplant recipients

  2015cites this paper
• Plasma stable, pH-sensitive non-ionic surfactant vesicles simultaneously enhance antiproliferative effect and selectivity of Sirolimus

  2015cites this paper
• Chapter 35 – Cancer in Dialysis and Kidney Transplant Patients

  2014cites this paper
• Incidental renal cell carcinoma originating from a native kidney after en-bloc resection for adrenal carcinoma in a kidney transplant recipient.

  2014cites this paper
• Beyond calcineurin inhibitors: emerging agents in kidney transplantation

  2013cites this paper
• Molecular Pathogenesis of B-Cell Posttransplant Lymphoproliferative Disorder: What Do We Know So Far?

  2013cites this paper
• PI3Kδ Inhibition Augments the Efficacy of Rapamycin in Suppressing Proliferation of Epstein−Barr Virus (EBV)+ B Cell Lymphomas

  2013cites this paper
• Lymphoproliférations post-transplantation d’organe solide

  2013cites this paper
• Managing Post-Transplant Lymphoproliferative Disorders in Solid-Organ Transplant Recipients

  2012cites this paper
• Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens

  2012cites this paper
• Skin cancer in organ transplant recipients

  2012cites this paper
• 4 Posttransplant Lymphoproliferative Disorders Following Kidney Transplantation

  2012cites this paper
• Viral Infection in Renal Transplant Recipients

  2012cites this paper
• Posttransplant lymphoproliferative disorder with lung involvement in a renal transplant recipient.

  2011cites this paper
• Organ transplantation from deceased donors with cancer: is it safe?

  2011cites this paper
• Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside

  2011cites this paper
• Posttransplant Lymphoproliferative Disorders Following Kidney Transplantation

  2011cites this paper
• The role of mTOR inhibition in renal transplant immune suppression

  2011cites this paper
• The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma

  2011cites this paper
• Walking on the Molecular Pathway: m-TOR Inhibition in the Liver Transplant Setting

  2011cites this paper
• Management of posttransplant lymphoproliferative disorders following solid organ transplant: an update

  2011cites this paper
• Merkel cell carcinoma of skin-current controversies and recommendations

  2011cites this paper
• Native Nephrectomy for Renal Cell Carcinoma in Transplant Recipients

  2011cites this paper
• A review of the epidemiology and treatment of Merkel cell carcinoma

  2011cites this paper
• Updating progress in sarcoma therapy with mTOR inhibitors.

  2011cites this paper
• [Medical complications of lung transplantation].

  2010cites this paper
• [Complications of lung transplantation].

  2010cites this paper
• Complications non chirurgicales de la transplantation pulmonaire

  2010cites this paper
• Results of the conversion to everolimus in renal transplant recipients with posttransplantation malignancies.

  2010cites this paper
• Merkel Cell Carcinoma of the Gluteal Region with Ipsilateral Metastasis into the Pancreatic Graft of a Patient after Combined Kidney-Pancreas Transplantation

  2010cites this paper
• Characteristics of Thoracic Malignancies That Occur After Solid-Organ Transplantation

  2010cites this paper
• Post-transplant lymphoproliferative disorders following solid-organ transplantation

  2010cites this paper
• Post‐transplant lymphoproliferative disorders in children: The role of chemotherapy in the era of rituximab

  2010cites this paper
• Regression of advanced melanoma upon withdrawal of immunosuppression: case series and literature review

  2010cites this paper
• Considerations in sirolimus use in the early and late post-transplant periods

  2009cites this paper
• Living‐donor renal transplantation of grafts with incidental renal masses after ex‐vivo partial nephrectomy

  2009cites this paper
• Use of rapamycin in the induction of tolerogenic dendritic cells.

  2009cites this paper
• The Role of mTOR Inhibitors in the Management of Posttransplant Malignancy

  2009cites this paper
• Manejo de tumores tras el trasplante renal

  2009cites this paper
• Lung Cancer and Lung Transplantation: A Review

  2009cites this paper
• Élaboration d'un anticorps chimère anti-gp350 comme traitement prophylactique éventuel des syndromes lymphoprolifératifs B chez les greffés

  2009cites this paper
• Mutagenicity of Immunosuppressive Medications among Renal Transplant Recipients

  2009cites this paper
• Chapter 33 – Cancer in Dialysis and Renal Transplant Patients

  2008cites this paper
• Epstein–Barr virus, rapamycin, and host immune responses

  2008cites this paper